Could a new probe spot hidden cancer cells?

NCT ID NCT07331532

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive probe called 68Ga-PFA2 for PET scans. It targets a protein called annexin A2, which is found at high levels in many cancers and helps them spread. Researchers want to see if this probe can find metastases in lung cancer patients better than current standard scans. Ten adults with confirmed lung cancer will be enrolled to compare the new probe's accuracy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-PFA2 (a radioactive imaging probe)
What this could lead to: If successful, this could provide a more accurate, non-invasive way to detect cancer spread, helping doctors tailor treatments earlier.
What could go wrong: This is a very small, early-phase study with only 10 participants, so results may not apply broadly. The probe's effectiveness compared to standard scans is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer exocrine pancreatic carcinoma lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS、LUNG NEOPLASMS、PANCREATIC NEOPLASMS EXPLORING THE DIAGNOSTIC POTENTIAL OF 68GA-PFA2 PET IMAGING IN ANNEXIN A2-POSITIVE TUMORS, INCLUDING BREAST CANCER, LUNG CANCER, AND PANCREATIC CANCER

Contacts and locations

Locations

Peking university first hospital nuclear medicine
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.